Investors & Media

March 5, 2018

Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the Cowen & Co. 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 P.M. ET in Boston.

A live webcast of the presentation can be accessed on the investor page of Sage's website at A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit

Source: Sage Therapeutics

Sage Therapeutics
Investor Contact:
Paul Cox, 617-299-8377
Media Contact:
Maureen L. Suda, 585-355-1134